Product Description
The CS060304 target is the same as MGL-3196, a novel THR-β agonist developed by Cascade, with highly specific enrichment in liver tissue. Compared to Resmetirom, CS060304 demonstrates significantly positive preclinical data, particularly in improving NAS scores and fibrosis in NASH mouse models. It exhibits characteristics of low effective dosage, significant efficacy, and good tolerability. Its clinical trial approval is expected to provide NASH patients with a safe and effective potential treatment option, making it a potential best-in-class potent selective THR-β agonist. (Sourced from: https://www.cnbio.xyz/2024/04/cascade-submits-ind-application-for-CS060304.html)
Mechanisms of Action: THR-B Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cascade Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CS060304-FIH-CN-I-01 | P1 |
Not yet recruiting |
Healthy Volunteers |
2025-04-29 |